BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17473570)

  • 1. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
    Shorr AF; Jackson WL; Weiss BM; Moores LK
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
    Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
    Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD; Goeree R; Crowther MA; O'Brien BJ
    Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
    McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
    Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
    Wilbur K; Lynd LD; Sadatsafavi M
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.
    Shorr AF; Ramage AS
    Crit Care Med; 2001 Sep; 29(9):1659-65. PubMed ID: 11546959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
    Wein L; Wein S; Haas SJ; Shaw J; Krum H
    Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
    Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
    Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD; Goeree R; Crowther MA; O'Brien BJ
    Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 18000316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.
    Pineo GF; Hull RD
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):489-500. PubMed ID: 19520676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economics of low-molecular weight heparins.
    Rutschmann OT; Matchar DB
    Am J Manag Care; 2000 Nov; 6(20 Suppl):S1054-65; quiz 1066-7. PubMed ID: 11484305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study.
    Goldstein JL; Larson LR; Yamashita BD; Fain JM; Schumock GT
    Am J Gastroenterol; 2001 Aug; 96(8):2360-6. PubMed ID: 11513175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
    Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
    Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery.
    Dainty L; Maxwell GL; Clarke-Pearson DL; Myers ER
    Gynecol Oncol; 2004 May; 93(2):366-73. PubMed ID: 15099947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.